phosphorylcholine has been researched along with Libman-Sacks Disease in 17 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glomerulonephritis was addressed by detection of proteinuria, and immunoglobulin complex deposition in the mesangium of the kidneys of the mice by immunofluorescence." | 5.42 | Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. ( Barshak, I; Bashi, T; Ben-Ami Shor, D; Blank, M; Fridkin, M; Gendelman, O; Shoenfeld, Y; Versini, M; Volkov, A, 2015) |
| "IgM antibodies against phosphorylcholine (anti-PC) are negatively associated with atherosclerosis, cardiovascular disease (CVD) and systemic lupus erythematosus (SLE), where the risk of CVD and atherosclerosis is high." | 3.88 | IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors. ( Ajeganova, S; Frostegård, J; Gillgren, P; Liu, A; Lundström, SL; Rahman, M; Steuer, J; Sun, J; Zhang, B; Zubarev, RA, 2018) |
| "Atherosclerosis is the main cause of CVD in the general population, and in SLE, increased atherosclerosis, especially the prevalence of atherosclerotic plaques, has been demonstrated." | 3.01 | Systemic lupus erythematosus and cardiovascular disease. ( Frostegård, J, 2023) |
| "Atherosclerosis is a chronic inflammatory disease characterized by the presence of activated immune-competent cells in the lesions, producing mainly proinflammatory cytokines." | 2.45 | Natural antibodies against phosphorylcholine in cardiovascular disease. ( de Faire, U; Frostegård, J, 2009) |
| "Glomerulonephritis was addressed by detection of proteinuria, and immunoglobulin complex deposition in the mesangium of the kidneys of the mice by immunofluorescence." | 1.42 | Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. ( Barshak, I; Bashi, T; Ben-Ami Shor, D; Blank, M; Fridkin, M; Gendelman, O; Shoenfeld, Y; Versini, M; Volkov, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Frostegård, J | 6 |
| Sun, J | 1 |
| Lundström, SL | 1 |
| Zhang, B | 1 |
| Zubarev, RA | 1 |
| Steuer, J | 1 |
| Gillgren, P | 1 |
| Rahman, M | 2 |
| Ajeganova, S | 1 |
| Liu, A | 2 |
| Villamil-Gómez, WE | 1 |
| Calderón-Gomezcaseres, Á | 1 |
| Rodriguez-Morales, AJ | 1 |
| López, P | 1 |
| Rodríguez-Carrio, J | 1 |
| Martínez-Zapico, A | 1 |
| Pérez-Álvarez, ÁI | 1 |
| Benavente, L | 1 |
| Caminal-Montero, L | 1 |
| Suárez, A | 1 |
| Grönwall, C | 2 |
| Reynolds, H | 1 |
| Kim, JK | 1 |
| Buyon, J | 1 |
| Goldberg, JD | 1 |
| Clancy, RM | 1 |
| Silverman, GJ | 2 |
| Bashi, T | 1 |
| Blank, M | 2 |
| Ben-Ami Shor, D | 1 |
| Fridkin, M | 1 |
| Versini, M | 1 |
| Gendelman, O | 1 |
| Volkov, A | 1 |
| Barshak, I | 1 |
| Shoenfeld, Y | 2 |
| Sing, S | 1 |
| Golabkesh, Z | 1 |
| Fiskesund, R | 1 |
| Gustafsson, T | 2 |
| Jogestrand, T | 2 |
| Frostegård, AG | 1 |
| Hafström, I | 1 |
| Su, J | 2 |
| Hua, X | 2 |
| Concha, H | 1 |
| Svenungsson, E | 1 |
| Cederholm, A | 1 |
| Zandman-Goddard, G | 1 |
| de Faire, U | 2 |
| Anania, C | 1 |
| Vikström, M | 1 |
| Heimbürger, M | 1 |
| Akhter, E | 1 |
| Oh, C | 1 |
| Burlingame, RW | 1 |
| Petri, M | 1 |
| Das, T | 1 |
| Sen, AK | 1 |
| Kempf, T | 1 |
| Pramanik, SR | 1 |
| Mandal, C | 2 |
| Sharma, A | 1 |
| Isenberg, DA | 1 |
| Diamond, B | 1 |
| Carson, MJ | 1 |
| Lo, D | 1 |
| Kabarowski, JH | 1 |
| Zhu, K | 1 |
| Le, LQ | 1 |
| Witte, ON | 1 |
| Xu, Y | 1 |
| Zouali, M | 1 |
| Migliorini, P | 1 |
| Stollar, DB | 1 |
3 reviews available for phosphorylcholine and Libman-Sacks Disease
| Article | Year |
|---|---|
Systemic lupus erythematosus and cardiovascular disease.
Topics: Antibodies, Antiphospholipid; Atherosclerosis; Cardiovascular Diseases; Humans; Inflammation; Lupus | 2023 |
Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.
Topics: Anti-Inflammatory Agents; Antibodies, Anti-Idiotypic; Antiphospholipid Syndrome; Humans; Immunoglobu | 2009 |
Natural antibodies against phosphorylcholine in cardiovascular disease.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Immunoglobulin M; Lipoproteins, LDL; Lupu | 2009 |
14 other studies available for phosphorylcholine and Libman-Sacks Disease
| Article | Year |
|---|---|
IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors.
Topics: Atherosclerosis; Autoimmunity; Case-Control Studies; Cells, Cultured; Dendritic Cells; Female; Flow | 2018 |
Visceral leishmaniasis in a patient with systemic lupus erythematosus from Colombia, Latin America.
Topics: Adult; Antiprotozoal Agents; Colombia; Humans; Leishmaniasis, Visceral; Lupus Erythematosus, Systemi | 2019 |
IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile.
Topics: Adult; Atherosclerosis; Autoantibodies; Biomarkers; Carotid Arteries; Female; Humans; Immunoglobulin | 2020 |
Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus.
Topics: Adult; Autoantibodies; Biomarkers; Carotid Arteries; Female; Humans; Immunoglobulin M; Lupus Erythem | 2014 |
Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine.
Topics: Animals; Autoantibodies; Cytokines; Disease Models, Animal; Forkhead Transcription Factors; Glomerul | 2015 |
IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms.
Topics: Adult; Apoptosis; Atherosclerosis; B-Lymphocytes; Biomarkers; Carotid Intima-Media Thickness; CD3 Co | 2016 |
Natural antibodies against phosphorylcholine as potential protective factors in SLE.
Topics: Adult; Autoantibodies; Binding, Competitive; Cardiovascular Diseases; Cross Reactions; Endothelium, | 2008 |
Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus.
Topics: Autoantibodies; Autoantigens; Carotid Arteries; Enzyme-Linked Immunosorbent Assay; Female; Humans; I | 2010 |
IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antigens; Apoptosis; Autoantibodies; Cardiovascular Disease | 2012 |
Induction of glycosylation in human C-reactive protein under different pathological conditions.
Topics: Amino Acid Sequence; C-Reactive Protein; Electrophoresis, Polyacrylamide Gel; Galactose; Glucose; Gl | 2003 |
Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin.
Topics: Antibodies, Antinuclear; Cross Reactions; Humans; Immunoglobulin G; Immunoglobulin Isotypes; Lupus E | 2001 |
Immunology. The push-me pull-you of T cell activation.
Topics: Animals; Antigen Presentation; Antigens; Arteriosclerosis; B-Lymphocytes; Cell Cycle Proteins; Human | 2001 |
Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A.
Topics: Animals; Arteriosclerosis; Calcium; Cell Cycle Proteins; Cell Line; Chemotaxis, Leukocyte; Humans; J | 2001 |
Murine lupus anti-DNA antibodies cross-react with the hapten (4-hydroxy-5-iodo-3-nitrophenyl)acetyl, but immunization-induced anti-DNA antibodies do not.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Autoantibodies; Cross Reactions; DNA; DNA, Si | 1987 |